General information

Announcements(0)

Greetings from the Chair

Overview

Web abstract

Registration

Information for Speakers, Presenters and Chairs

Program

Sessions

Search presentations

General information 2

Abstract Submission (Oral/Poster Presentation)

pharm143_en.png

icon_20251203182619268.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

<br>Enter the password to view the abstracts.<br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Announcements

Profile management

Bookmark

Download PDF for print

Timetable

Development of SARS-CoV-2 fusion inhibitor peptides learned from HIV-1 study

Recently, development of mid-size drugs such as peptides and nucleotides becomes a new attractive modality because these drugs can possess advantages of both small molecular drugs and biopharmaceuticals. Since the first approval of the peptide hormone drug in 1960s, more than 60 kinds of peptide-based drugs have been approved and clinically used in Japan. In addition, since the first oligonucleotide therapeutics, Vitravene, was approved by FDA in 1998, a number of oligonucleotide therapeutics have been developed and their market size is expanding year by year. <br />The mid-size drugs contain a lot of molecules including peptides, oligonucleotides, glycans, lipids, and chimeric molecules. Therefore, researchers in various fields are actively conducting a wide variety of mid-side drug discovery researches. In this symposium “Frontiers in Mid-size Drug Research – Diverse Approaches to Mid-size Drug Development –,” six researchers in different fields will present the state of the art topics; “chimeric molecules for target protein degradation (Itoh),” “mitigation of off-target effects of antisense oligonucleotides (T. Yamamoto),” “cancer immunotherapy utilizing glycoconjugates (Manabe),” “drug discovery based on lysophospholipids (K. Yamamoto),” “exploration of drug seeds using mirror-image natural products and biomolecules (Oishi)” and “anti-SARS-CoV-2 peptides learned from HIV research (Tsuji).”

Frontiers in Mid-Size Drug Research -Diverse Approaches to Mid-size Drug Development-

The 143rd Annual Meeting of the Pharmaceutical Society of Japan (Sapporo)

Presentation Information

[S05-06]Development of SARS-CoV-2 fusion inhibitor peptides learned from HIV-1 study

Password required to view